Coronavirus: Moderna expects COVID-19 vaccine trial data for children aged 2-5 in March

In a statement to investors Wednesday, Moderna said it expects to be able to report the data for its vaccine trials in children ages 2-5 in March. The statement added that if the findings are positive, the company will proceed with regulatory filings for the vaccine.

>> Read more trending news

The CDC has only approved Moderna’s COVID-19 vaccine for adults ages 18 and over in the United States.

Moderna’s vaccine is authorized in Europe, the U.K., Australia and Canada for adolescents as young as 12, Reuters reported. Moderna has submitted applications in Europe, the U.K., Australia, and Canada for the vaccine in children as young as 6.

More coronavirus pandemic coverage:

>> Coronavirus: How long between exposure to the virus and the start of symptoms?

>> What are your chances of coming into contact with someone who has COVID-19? This tool will tell you

>> How to not let coronavirus pandemic fatigue set in, battle back if it does

Comments on this article